0001493152-26-007105 | 10-Q | XBRL Viewer

Print Document

OTHER INCOME (Details Narrative) - USD ($)	3 Months Ended
OTHER INCOME (Details Narrative) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
OtherIncomeAndExpensesLineItems [Line Items]
Interest income	$ 4,920,707	$ 789,381
Interest earned from lease agreement	21,000	$ 21,000
Consulting Service [Member]
OtherIncomeAndExpensesLineItems [Line Items]
Cash held at a financial institution	$ 71,850

- Definition

Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 310
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479255/942-310-S50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 310
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.H.2.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478116/942-310-S99-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 45
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477346/946-830-45-39

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

+ Details

PROPERTY, PLANT AND EQUIPMENT

3 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

5. PROPERTY, PLANT AND EQUIPMENT

	December 31, 2025			September 30, 2025
	Land, buildings and leasehold improvements			Land, buildings and leasehold improvements
Cost
Beginning of period	$	10,149,332		$	1,700,000
Additions – land		-			330,000
Additions – building		-			4,000,234
Additions – leasehold improvements		-			3,103,000
Additions – construction in progress		1,453,915			1,016,098
End of period		11,603,247			10,149,332

Accumulated depreciation
Beginning of period		(365,555	)		(10,393	)
Depreciation of building		(69,978	)		(133,975	)
Depreciation of leasehold improvements		(138,430	)		(221,187	)
End of period		(573,963	)		(365,555	)

Total property, plant and equipment, net	$	11,029,284		$	9,783,777

In August 2024, the Company purchased a 1.64-acre land package in the historic Heritage Center Industrial Park in Oak Ridge, Tennessee, for $1.7 million. The purchase included a 14,000 sq. ft., 2-story building to house the Company’s Nuclear Technology Branch. Depreciation was $30,353 and $94,351 for the three months ended December 31, 2025 and year ended September 30, 2025.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

5. PROPERTY, PLANT AND EQUIPMENT (continued)

In July 2025, the Company purchased a 2.75-acre land package in Oak Brook, Illinois, for $3.5 million. The purchase included a 23,537 sq. ft. building to serve as a regional demonstration and office facility to support the development of the Company’s KRONOS MMR™ Microreactor Energy System. Depreciation was $39,625 and $39,625 for the three months ended December 31, 2025 and year ended September 30, 2025.

Cover - shares	3 Months Ended
Cover - shares	Dec. 31, 2025	Feb. 16, 2026
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2026
Current Fiscal Year End Date	--09-30
Entity File Number	001-42044
Entity Registrant Name	NANO NUCLEAR ENERGY INC.
Entity Central Index Key	0001923891
Entity Tax Identification Number	88-0861977
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	10 Times Square
Entity Address, Address Line Two	30th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10018
City Area Code	(212)
Local Phone Number	634-9206
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	NNE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		52,082,794

LONG-TERM INVESTMENTS, RELATED PARTY (Details Narrative)	3 Months Ended
	Dec. 31, 2025 USD ($) ft²	Sep. 30, 2025 USD ($)	Jul. 31, 2025 ft²	Jul. 31, 2025 a	Aug. 31, 2024 USD ($)	Aug. 31, 2024 ft²	Aug. 31, 2024 a
InvestmentsAllOtherInvestmentsLineItems [Line Items]
Equity method investment	$ 2,000,000.0	$ 2,000,000.0
Investment	$ 2,000,000	$ 2,000,000
Area of land	7,000		23,537	2.75		14,000	1.64
Lease payment	$ 7,000
LIS Technologies Inc [Member]
InvestmentsAllOtherInvestmentsLineItems [Line Items]
Equity method investment					$ 2,000,000
Investment					$ 11,880,000

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References + Details

ACQUISITION OF ALIP TECHNOLOGY (Details Narrative) - USD ($)			3 Months Ended
	Dec. 31, 2024	Jun. 21, 2024	Dec. 31, 2025
Asset Acquisition [Line Items]
Contingent consideration	$ 1,294,750	$ 836,500	$ 1,250,500
Revaluation expense	$ 524,250		$ 727,500
ALIP Technology [Member]
Asset Acquisition [Line Items]
Number of shares issued for acquisitions		50,000
Cash consideration		$ 50,000
ALIP Technology [Member] \| Dr Maidana [Member]
Asset Acquisition [Line Items]
Number of shares issued for acquisitions		50,000
Cash consideration		$ 50,000

ACQUISITION OF ALIP TECHNOLOGY

3 Months Ended

Dec. 31, 2025

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

ACQUISITION OF ALIP TECHNOLOGY

7. ACQUISITION OF ALIP TECHNOLOGY

On June 21, 2024, the Company acquired a novel annular linear induction pump (“ALIP”) technology used in small nuclear reactor cooling (“ALIP Acquisition”) from noted physicist, research engineer and project manager Carlos O. Maidana, PhD. In connection with the transaction, Dr. Maidana agreed to collaborate with the Company as a consultant on further development of the ALIP technology with a view toward achieving SBIR Phase III Award status.

As part of this transaction, Dr. Maidana assigned to NANO all intellectual property rights associated with the ALIP technology and product, his work on the foregoing grants and the proposal for the SBIR Phase III program. As consideration for the ALIP Acquisition, the Company (i) issued 50,000 shares of Common Stock to Dr. Maidana and (ii) paid Dr. Maidana cash consideration of $50,000. Additionally, the Company agreed to deliver to Dr. Madana an additional (iii) 50,000 shares of Common Stock and (iv) cash consideration of $50,000, contingent upon the successful completion of the SBIR Phase III project prior to specific timetables. The Company anticipated that the completion of the SBIR Phase III project would occur, and therefore had calculated the contingent consideration at the closing price of NANO’s stock on the date of acquisition. The ALIP Acquisition was accounted for as an acquisition of in-process R&D that was fully expensed on the acquisition date as R&D costs.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

7. ACQUISITION OF ALIP TECHNOLOGY (Continued)

The ALIP Acquisition was recorded at its fair value as of June 21, 2024. The total purchase price was approximately $1.67 million and was comprised of the following:

SCHEDULE OF ALIP ACQUISITION

	Total
Cash (paid on closing)	$	50,000
Shares of Common Stock (issued on closing)		786,500
Contingent cash		50,000
Contingent Common Stock (fair value at closing)		786,500
Total purchase price	$	1,673,000

On June 21, 2024, the contingent cash and Common Stock obligation were recorded at its fair value of $836,500 based on the closing price of the Common Stock on the date of acquisition. At December 31, 2024, the contingent cash and Common Stock obligation were revalued to its fair value of $1,294,750 based on the closing price of the Common Stock on December 31, 2024, which resulted in a revaluation expense of $524,250. At December 31, 2025, the contingent cash and Common Stock obligation were revalued to its fair value of $1,250,500 based on the closing price of the Common Stock on December 31, 2025, which resulted in a revaluation recovery of $727,500.

SUBSEQUENT EVENTS

3 Months Ended

Dec. 31, 2025

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

10. SUBSEQUENT EVENTS

The Company has evaluated all events or transactions that occurred after December 31, 2025 through the date that the unaudited condensed consolidated financial statements were issued. During this period, there were no material subsequent events requiring disclosure except as stated as follows:

Between January 1, 2026 and the date that the unaudited condensed consolidated financial statements were issued, 1,000 warrants were exercised to purchase 500 Common Stock at an exercise price of $20.00 per share generating gross proceeds of approximately $10,000, 1,000 warrants were exercised to purchase 500 Common Stock at an exercise price of $17.00 per share generating gross proceeds of approximately $8,500, 1,150,000 stock options were exercised to purchase 1,150,000 shares of Common Stock at an exercise price of $1.50 per share generating proceeds of approximately $1,725,000, and 350,000 stock options were exercised to purchase 350,000 shares of Common Stock at an exercise price of $3.00 per share generating proceeds of approximately $1,050,000.

EQUITY

3 Months Ended

Dec. 31, 2025

Equity [Abstract]

EQUITY

4. EQUITY

The Company is authorized to issue 275,000,000 shares of Common Stock and 25,000,000 shares of preferred stock, with a par value of $0.0001 per share. No shares of preferred stock were outstanding during the periods presented. Holders of Common Stock are entitled to one vote per share.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

4. EQUITY (Continued)

Issuance of Common Stock for Cash

Initial Public Offering

On May 7, 2024, the Company consummated a firm commitment underwritten initial public offering (the “IPO Offering”) of an aggregate of 2,562,500 shares of Common Stock at a price of $4.00 per share (the “IPO Offering Price”), generating gross proceeds of $10,250,000, and net proceeds (after deducting discounts and offering expenses) of approximately $9.0 million. In connection with the IPO Offering, the Company granted the lead managing underwriter an option (the “IPO Over-Allotment Option”), exercisable for 30 days from May 7, 2024, to purchase up to an additional 384,375 shares of Common Stock (the “IPO Over-allotment Shares”) from the Company at the Offering Price, less the underwriting discount, to cover over-allotments in the Offering.

On May 21, 2024, the underwriter exercised the IPO Over-Allotment Option in full, and on May 22, 2024, the closing of the purchase of the IPO Over-Allotment Shares occurred, generating gross proceeds to the Company of $1,537,500 and net proceeds of approximately $1.4 million. In connection with the IPO Offering, the Company also issued such lead managing underwriter 179,375 warrants exercisable for 179,375 shares of Common Stock at an exercise price per share of $5.00 with expiry on May 10, 2029. In connection with the IPO Offering and IPO Over-Allotment Option, the Company charged issuance costs of $1,538,405 to additional paid-in capital during the year ended September 30, 2024.

July 2024 Firm Commitment Public Offering

On July 15, 2024, the Company consummated a firm commitment underwritten follow-on public offering (the “July 2024 Follow-on Offering”) of an aggregate of 900,000 units, consisting of an aggregate of 900,000 shares of Common Stock and 900,000 warrants to purchase up to 450,000 shares of Common Stock (the “July 2024 Follow-on Warrants”) based on an offering price of $20.00 per unit (the “July 2024 Follow-on Offering Price”), generating gross proceeds of $18 million, and net proceeds (after deducting discounts and offering expenses) of approximately $16.1 million. In connection with the July 2024 Follow-on Offering, the Company granted the lead managing underwriter an option (“July 2024 Follow-on Over-allotment Option”), exercisable for 30 days from July 15, 2024, to purchase up to an additional 135,000 shares of Common Stock (the “July 2024 Follow-on Over-allotment Shares”) and 135,0000 Warrants to purchase 67,500 shares of Common Stock (the “July 2024 Follow-on Over-allotment Warrants”) from the Company at the July 2024 Follow-on Offering Price, less underwriting discounts and other July 2024 Follow-on Offering expenses, to cover over-allotments in the July 2024 Follow-on Offering. On July 12, 2024, the underwriter exercised the July 2024 Follow-on Over-allotment Option in full with respect to the July 2024 Follow-on Over-allotment Warrants, which closed on July 15, 2024 for nominal consideration.

On July 16, 2024, the underwriter exercised the July 2024 Follow-on Over-allotment Option in full, and on July 18, 2024, the closing of the purchase of the July 2024 Follow-on Over-Allotment Shares occurred, generating gross proceeds to the Company of approximately $2.7 million and net proceeds of approximately $2.5 million. In connection with the July 2024 Follow-on Offering, the Company also issued such lead managing underwriter 63,000 warrants exercisable for 63,000 shares of Common Stock at an exercise price per share of $25.00 with expiry on July 15, 2029. In connection with the July 2024 Follow-on Offering and July 2024 Follow-on Over-allotment Option, the Company charged issuance costs of $2,091,424 to additional paid-in capital during the year ended September 30, 2024.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

4. EQUITY (Continued)

October 2024 Firm Commitment Public Offering

On October 23, 2024, the Company consummated a firm commitment underwritten follow-on public offering (the “October 2024 Follow-on Offering”) of an aggregate of 2,117,646 units, consisting of an aggregate of 2,117,646 shares of Common Stock and 2,117,646 warrants to purchase up to 1,058,823 shares of Common Stock (the “October 2024 Follow-on Warrants”) based on an offering price of $17.00 per unit (the “October 2024 Follow-on Offering Price”), generating gross proceeds of approximately $36 million, and net proceeds (after deducting discounts and offering expenses) of approximately $32.3 million. In connection with the October 2024 Follow-on Offering, the Company granted the lead managing underwriter an option (“October 2024 Follow-on Over-allotment Option”), exercisable for 30 days from October 25, 2024, to purchase up to an additional 317,646 shares of Common Stock (the “October 2024 Follow-on Over-allotment Shares”) and 317,646 warrants to purchase 158,823 shares of Common Stock (the “October 2024 Follow-on Over-allotment Warrants”) from the Company at the October 2024 Follow-on Offering Price, less underwriting discounts and other October 2024 Follow-on Offering expenses, to cover over-allotments in the October 2024 Follow-on Offering. On October 23, 2024, the underwriter partially exercised the October 2024 Follow-on Over-allotment Option for the October 2024 Follow-on Over-allotment Warrants (which option closed on October 25, 2024 for nominal consideration). On October 28, 2024, the lead underwriter exercised the October 2024 Follow-on Over-allotment Option in full with respect to the October 2024 Follow-on Over-allotment Shares, and on October 29, 2024, the closing of the purchase of the October 2024 Follow-on Over-Allotment Shares occurred, generating gross proceeds to the Company of approximately $5.4 million and net proceeds of approximately $4.9 million. In connection with the October 2024 Follow-on Offering, the Company issued such lead managing underwriter 105,882 warrants exercisable for 105,882 shares of Common Stock at an exercise price per share of $21.25 with expiry on October 29, 2029. In connection with the October 2024 Follow-on Over-allotment Option, the Company also issued such lead managing underwriter 15,882 warrants exercisable for 15,882 shares of Common Stock at an exercise price per share of $21.25 with expiry on October 29, 2029.

November 2024 Private Placement

On November 24, 2024, the Company, entered into a securities purchase agreement (the “November 2024 SPA”) with three accredited institutional investors (the “Investors”), pursuant to which the Company agreed to offer and sell an aggregate of $60,000,048 of securities of the Company in a private placement (the “November 2024 Private Placement”), consisting of (i) 2,500,002 shares (“PIPE Shares”) of Common Stock and (ii) warrants to purchase up to 2,500,002 shares of Common Stock (the “PIPE Warrants”). The November 2024 Private Placement closed on November 27, 2024. After deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately $55,122,000. The Company intends to use these net proceeds for general working capital and general corporate purposes, which could include potential acquisitions of complementary businesses or assets. Pursuant to the November 2024 SPA, the Company issued and sold the PIPE Shares and associated PIPE Warrants at a combined purchase price of $24.00 per share. The PIPE Warrants have a term of five (5) year with an exercise price of $26.00 per share and will be exercisable immediately upon issuance of the PIPE Warrants. On November 24, 2024, in connection with the Private Placement, the Company entered into a registration rights agreement with the Investors (the “Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of the PIPE Shares and the shares of Common Stock issuable upon exercise of the PIPE Warrants by no later than January 15, 2025 (the date of filing, the “Filing Date”), with such registration statement to be effective within 30 days of the Filing Date (if such registration statement is not subject to review by the SEC), or within 60 days after the Filing Date (if such registration statement is subject to limited or full review by the SEC). The Company initially filed a registration statement on Form S-1 covering the resale of these securities on January 14, 2025, which was declared effective by the SEC on January 24, 2025. The Investors are also entitled (subject to certain exceptions) to customary piggyback registration rights during the period in which the registration statement is effective. The Benchmark Company, LLC acted as placement agent for the Private Placement and received a cash fee equal to 6.0% of the gross proceeds received by the Company in the Private Placement, a non-accountable expense allowance equal to 1% of the gross proceeds received by the Company from the Private Placement, and reimbursement of up to $175,000 in legal expenses.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

4. EQUITY (Continued)

May 2025 Private Placement

On May 26, 2025, the Company, entered into a securities purchase agreement (the “May 2025 SPA”) with six accredited institutional investors (the “May 2025 Investors”), pursuant to which the Company agreed to offer and sell 3,888,889 shares (“May 2025 PIPE Shares”) of Common Stock of the Company in a private placement (the “May 2025 Private Placement”) for gross proceeds of $105,000,003. Pursuant to the May 2025 SPA, the Company issued and sold the May 2025 PIPE Shares in the May 2025 Private Placement at a purchase price of $27.00 per share. The May 2025 Private Placement closed on May 28, 2025. After deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately $99 million. The Company intends to use these net proceeds for research and development, marketing, general working capital and general corporate purposes, which could include potential acquisitions of complementary businesses or assets. The May 2025 SPA includes standard representations, warranties and covenants of the Company and May 2025 Investors, including a restriction on future issuances of the Company’s capital stock or filing a registration statement or any amendment or supplement thereto (subject to certain exceptions) for a period of thirty (30) days following effectiveness of the Company’s May 2025 Resale Registration Statement (as defined below) required by the May 2025 Registration Rights Agreement (as defined below). Also on May 26, 2025, in connection with the May 2025 Private Placement, the Company entered into a registration rights agreement with the Investors (the “May 2025 Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of the May 2025 PIPE Shares (the “May 2025 Resale Registration Statement”) by no later than June 10, 2025 (the date of filing, the “May 2025 Filing Date”), with the May 2025 Resale Registration Statement to be effective within 30 days of the May 2025 Filing Date (if it is not subject to review by the SEC), or within 60 days after the Filing Date (if it is subject to full review by the SEC). The May 2025 Investors are also entitled (subject to certain exceptions) to customary piggyback registration rights during the period in which the May 2025 Resale Registration Statement is effective. The Company initially filed the May 2025 Registration Rights Agreement covering the May 2025 PIPE Shares on June 9, 2025, which was declared effective by the SEC on June 18, 2025. Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as placement agent for the Private Placement (the “May 2025 Placement Agent”) under a placement agency agreement with the Company (“May 2025 Placement Agency Agreement”), pursuant to which it received a cash fee equal to 5.0% of the gross proceeds received by the Company in the Private Placement, and reimbursement of $150,000 in legal expenses.

October 2025 Private Placement

On October 7, 2025, the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with six institutional investors (the “Investors”), pursuant to which the Company agreed to offer and sell 8,490,767 shares (“Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), in a private placement (the “Private Placement”) for gross proceeds of approximately $400,000,000. Pursuant to the Purchase Agreement, the Company issued and sold the Shares in the Private Placement at a purchase price of $47.11 per share. The Private Placement closed on October 10, 2025. After deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately $378,500,000. The Company intends to use these net proceeds to advance development, construction and regulatory licensing activities for its lead micro nuclear reactor program, the KRONOS MMR^™ Energy System, continue development of its other micro reactor projects and other nuclear energy related business lines, pursue potential strategic acquisitions, and for general corporate purposes. Pursuant to the Purchase Agreement the Company included a resale prospectus in the next amendment to its registration statement on Form S-3 initially filed with the SEC on July 25, 2025 (File No.: 333-288982) covering the resale of the Shares (the “Resale Registration Statement”) which was amended and filed on October 22, 2025 (the date of filing, the “Filing Date”), and with the Resale Registration Statement to be effective within 30 days following the later of (i) the Filing Date, and (ii) the second business day after the date on which the United States Federal government shutdown has concluded and the SEC has reopened for operations, if it is not subject to review by the SEC. The Company will have an additional 30 days to cause the Resale Registration Statement to become effective, if it is subject to full review by the SEC. As of the date of these financial statements, the Resale Registration Statement remains under review by the SEC. The Purchase Agreement includes standard representations, warranties and covenants of the Company and Investors, including a restriction on future issuances of the Company’s capital stock or filing a registration statement or any amendment or supplement thereto (subject to certain exceptions) for a period of thirty (30) days following effectiveness of the Resale Registration Statement. Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as placement agent for the Private Placement (the “Placement Agent”) under a placement agency agreement with the Company (“Placement Agency Agreement”), pursuant to which it received a cash fee equal to 5.0% of the gross proceeds received by the Company in the Private Placement, and reimbursement of $200,000 in legal expenses.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

4. EQUITY (Continued)

Equity-Based Compensation

Stock-Based Compensation

Stock Options

On February 10, 2023, and June 7, 2023, the Company adopted two distinct stock option plans which are referred to individually, as the 2023 Stock Option Plan #1 and the 2023 Stock Option Plan #2 (collectively, the “2023 Stock Option Plans”). On April 23, 2025 (the “Effective Date”), the Company’s shareholders approved, and the Company adopted an equity incentive plan (the “2025 Equity Plan”) whereby a total of 4,750,000 shares plus 679,440 shares that were available for issuance under the 2023 Stock Option Plans as of the 2025 Equity Plan’s Effective Date were available for future awards under the 2025 Equity Plan. This amount may increase annually on January 1 each year beginning on January 1, 2026 to January 1, 2035, by an amount equal to the lesser of (i) 5% of the Common Stock outstanding on the last day of the immediately preceding calendar year and (ii) such smaller number of shares of Common Stock as determined by the board of directors (the “Board”) or a committee of the Board. The shares of Common Stock subject to the 2025 Equity Plan may be authorized, but unissued, or reacquired shares. As of December 31, 2025, an aggregate total of 5,295,300 options have been issued under the 2023 Stock Option Plans and 2025 Equity Plan and 4,633,926 are available for issuance under the 2025 Equity Plan.

The Company did not grant any stock options during the three months ended December 31, 2025 or 2024. However, during the three months ended December 31, 2025, 195,000 stock options were exercised with exercise prices ranging from $1.50 - $3.00 resulting in $540,000 of cash proceeds and during the three months ended December 31, 2024, 490,000 stock options were exercised with exercise prices ranging from $1.50 - $3.00 resulting in $1,207,500 cash proceeds.

During the three months ended December 31, 2025 and 2024, total stock-based compensation for stock options expected to vest was $312,128 and $0. As of December 31, 2025, there is $5,931,692 remaining stock compensation expense to be recognized corresponding to future vesting dates over a weighted average period of 5.14 years which will occur between 2026 and 2031.

Option Activity

A summary of cumulative option activity under the 2023 Stock Option Plans and the 2025 Equity Plan is as follows:

SCHEDULE OF CUMULATIVE OPTION ACTIVITY

	Options outstanding
	Number of shares			Weighted- average exercise price per share		Weighted- average contractual term (in years)		Aggregate intrinsic value (in thousands)

Outstanding – September 30, 2024		3,539,000		$	2.34		1.59	$	42,720
Options granted		1,184,300			28.01				—
Options forfeited		(5,300	)		28.32		—		—
Options exercised		(944,000	)		2.55		—		—
Outstanding – September 30, 2025		3,774,000		$	10.31		3.25	$	106,626
Options exercised		(195,000	)		2.77		—		—
Outstanding – December 31, 2025		3,579,000		$	10.72		3.13	$	52,292
Exercisable at the end of period		3,235,000		$	8.99		2.50	$	52,292

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

4. EQUITY (Continued)

Equity-Based Compensation (Continued)

Stock-Based Compensation (Continued)

Restricted Stock Units (“RSUs”)

On November 13, 2025, the Company granted 423,766 RSUs to various consultants and key employees. The aggregate grant-date fair value of the RSUs was $14,280,914 or $33.70 per share based on the market price of our stock on the date of grant. The RSUs vest as follows: 392,694 RSUs vest one-third on the grant-date anniversary over three years; 11,872 RSUs vest on the grant-date anniversary, and 19,200 vest 50% on the six month anniversary of the grant-date with remaining vesting on the grant-date anniversary. As of December 31, 2025, there are 757,014 unvested RSUs with a weighted average grant-date fair value of $30.99.

During the three months ended December 31, 2025, we modified an RSU for 20,000 shares of common stock granted on June 3, 2025 to vest 50% on the six-month anniversary of the grant-date with the remaining vesting on the grant-date anniversary which was previously set to vest 100% on the grant-date anniversary.

During the three months ended December 31, 2025, we recognized stock-based compensation for RSUs expected to vest of $1,760,562. As of December 31, 2025, we have unrecognized compensation of $21,336,866 which will be recognized over a weighted-average period of 2.59 years.

Restricted Stock Unit Activity

A summary of cumulative restricted stock unit activity under the 2025 Equity Plan is as follows:

	RSUs outstanding
	Number of shares			Weighted- average grant date fair value per share		Aggregate fair value (in thousands)

Outstanding –September 30, 2024		—		$	—	$	—
RSUs granted		350,748			29.18		10,235
Outstanding and unvested – September 30, 2025		350,748		$	29.18	$	10,235
RSUs granted		423,766			29.18		10,235
RSUs vested (stock issued)		(17,500	)		29.18		—
Outstanding and unvested – December 31, 2025		757,014		$	29.18	$	10,235

Warrant Activity

A summary of cumulative warrant activity is as follows:

	Warrant Shares outstanding
				Weighted- average		Weighted- average
	Number of			exercise price		contractual term
	shares			per share		(in years)

Outstanding – September 30, 2024		817,864		$	17.28		4.79
Warrants issued		3,717,648			23.05		5.00
Warrants exercised		(1,408,193	)		16.71		-
Outstanding – September 30, 2025		3,127,319		$	24.40		4.12
Warrants exercised		(140,169	)		17.44		-
Outstanding – December 31, 2025		2,987,150		$	24.72		3.88

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

USNC ASSET ACQUISITION (Tables)

3 Months Ended

Dec. 31, 2025

Usnc Asset Acquisition

SCHEDULE OF ALLOCATION OF CONSIDERATION

The fair value allocation of the consideration transferred is as follows:

SCHEDULE OF ALLOCATION OF CONSIDERATION

	Total
Cash consideration paid	$	8,500,000
Less: Value of Consent Assets (subject to Canadian Consents) held in escrow		(250,000	)
Add: Assumed liabilities related to Designated Contracts (excluding Canadian Contracts)		825,045
Total fair value of Acquired IPR&D Assets	$	9,075,045

SCHEDULE OF EXPECTED ANNUAL MINIMUM LEASE PAYMENTS (Details) - USD ($)	Dec. 31, 2025	Sep. 30, 2025
Right-of-use Assets And Lease Liabilities
2026	$ 471,998
2027	641,992
2028	658,041
2029	674,493
Thereafter	1,142,669
Total future minimum lease payments, undiscounted	3,589,193
Less: Imputed interest for leases in excess of one year	(903,027)
Present value of future minimum lease payments	2,686,166
Less: Current portion of lease liabilities	(540,801)	$ (534,128)
Total lease liabilities, less current portion	$ 2,145,365	$ 2,261,414

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Sep. 30, 2024	$ 3,072	$ 49,038,165	$ (17,433,781)		$ 31,607,456
Balance, shares at Sep. 30, 2024	30,715,663
Common stock issuances	$ 494	101,399,518			101,400,012
Common stock issuances, shares	4,935,294
Offering costs		(9,058,856)			(9,058,856)
Exercise of warrants	$ 60	8,014,226			8,014,286
Exercise of warrants, shares	601,142
Exercise of stock options	$ 49	1,207,451			1,207,500
Exercise of stock options, shares	490,000
Net loss			(3,113,362)		(3,113,362)
Balance at Dec. 31, 2024	$ 3,675	150,600,504	(20,547,143)		130,057,036
Balance, shares at Dec. 31, 2024	36,742,099
Balance at Sep. 30, 2024	$ 3,072	49,038,165	(17,433,781)		$ 31,607,456
Balance, shares at Sep. 30, 2024	30,715,663
Exercise of stock options, shares					944,000
Net loss					$ (40,067,076)
Balance at Sep. 30, 2025	$ 4,173	280,065,412	(57,500,857)		222,568,728
Balance, shares at Sep. 30, 2025	41,738,358
Common stock issuances	$ 850	399,999,183			400,000,033
Common stock issuances, shares	8,490,767
Offering costs		(21,520,711)			(21,520,711)
Exercise of warrants	$ 14	2,445,034			2,445,048
Exercise of warrants, shares	140,169
Exercise of stock options	$ 19	539,981			$ 540,000
Exercise of stock options, shares	195,000				195,000
Equity-based compensation		2,072,690			$ 2,072,690
Equity-based compensation, shares	17,500
Net loss			(6,516,279)		(6,516,279)
Accumulated other comprehensive income loss				(10,720)	(10,720)
Balance at Dec. 31, 2025	$ 5,056	$ 663,601,589	$ (64,017,136)	$ (10,720)	$ 599,578,789
Balance, shares at Dec. 31, 2025	50,581,794

EQUITY (Details Narrative) - USD ($)													3 Months Ended		4 Months Ended	12 Months Ended
EQUITY (Details Narrative) - USD ($)	Nov. 13, 2025	Oct. 10, 2025	Oct. 07, 2025	Jun. 03, 2025	May 26, 2025	Nov. 24, 2024	Oct. 29, 2024	Oct. 23, 2024	Jul. 18, 2024	Jul. 15, 2024	May 22, 2024	May 07, 2024	Dec. 31, 2025	Dec. 31, 2024	Jun. 07, 2023	Sep. 30, 2025	Sep. 30, 2024
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized													275,000,000			275,000,000
Preferred stock, shares authorized													25,000,000			25,000,000
Preferred stock, par value													$ 0.0001			$ 0.0001
Preferred stock, shares outstanding													0			0
Additional paid in capital issuance costs													$ 21,520,711	$ 9,058,856
Net proceeds from issuance of common stock													400,000,033	101,400,012
Stock issuance costs													21,520,711	9,058,856
Proceds from private placement													$ 378,000,000
Common stock , par value													$ 0.0001			$ 0.0001
Common stock available for issuance													3,579,000			3,774,000	3,539,000
Shares stock option exercised													195,000			944,000
Exercise prices													$ 2.77			$ 2.55
Cash proceeds													$ 540,000	$ 1,207,500
Stock compensation expense													$ 5,931,692
Weighted average period													5 years 1 month 20 days
2023 Stock Option Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock available for issuance															679,440
Share based compensation description															This amount may increase annually on January 1 each year beginning on January 1, 2026 to January 1, 2035, by an amount equal to the lesser of (i) 5% of the Common Stock outstanding on the last day of the immediately preceding calendar year and (ii) such smaller number of shares of Common Stock as determined by the board of directors (the “Board”) or a committee of the Board. The shares of Common Stock subject to the 2025 Equity Plan may be authorized, but unissued, or reacquired shares
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Market price per share	$ 33.70
Stock compensation expense													$ 1,760,562
Restricted stock units, granted	423,766												20,000
Restricted stock units, fair value	$ 14,280,914
Restricted stock units, percent				50.00%									100.00%
Unvested RSUs	757,014
Weighted average grant-date fair value	$ 30.99
RSU unrecognized compensation													$ 21,336,866
RSU weighted-average period													2 years 7 months 2 days
Restricted Stock Units (RSUs) [Member] \| One Third Grant Date Anniversary [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted stock units, one-third vested	392,694
Restricted Stock Units (RSUs) [Member] \| Grant Date Anniversary [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted stock units, one-third vested	11,872
Restricted Stock Units (RSUs) [Member] \| Six Month Grant Date Anniversary [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted stock units, one-third vested				19,200
2025 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock available for issuance															4,750,000
Common stock available for issuance													4,633,926
2023 Stock Option Plans [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock available for issuance													5,295,300
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Price per share						$ 26.00
Market price per share			$ 47.11			$ 24.00
Proceds from private placement						$ 60,000,048
Warrants and Rights Outstanding, Term						5 years
Cash fee percentage		5.00%				6.00%
Non accountable expense allowance percentage						1.00%
Legal expenses		$ 200,000				$ 175,000
Sale of common stock			8,490,767
Common stock , par value			$ 0.0001
Lead Managing Underwriter [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant issued									63,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares													8,490,767	4,935,294
Number of shares of warrants								105,882
Additional paid in capital issuance costs
Net proceeds from issuance of common stock								$ 32,300,000
Warrants exercised								105,882
Shares stock option exercised													195,000	490,000
Cash proceeds													$ 19	$ 49
Vested stock option													$ 312,128	$ 0
Common Stock [Member] \| Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise prices													$ 1.50	$ 1.50
Common Stock [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise prices													$ 3.00	$ 3.00
Common Stock [Member] \| Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares						2,500,002
Number of shares of warrants						2,500,002
Common Stock [Member] \| Lead Managing Underwriter [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares									63,000
Market price per share									$ 25.00
Stock issuance costs									$ 2,091,424
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares												2,562,500
Price per share												$ 4.00
Proceeds from issuance initial public offering												$ 10,250,000
Net proceeds												$ 9,000,000.0
Number of shares of warrants											179,375
Price per share											$ 5.00
Additional paid in capital issuance costs																	$ 1,538,405
IPO [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of warrants											179,375
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares												384,375
Proceeds from issuance initial public offering											$ 1,537,500
Net proceeds											$ 1,400,000
Over-Allotment Option [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares								158,823
Number of shares of warrants								317,646
Gross proceeds from issuance of common stock							$ 5,400,000
Net proceeds from issuance of common stock							$ 4,900,000
Purchase of common stock								317,646
July 2024 Firm Commitment Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares										900,000
Warrants to purchase shares										900,000
Market price per share										$ 20.00
July 2024 Firm Commitment Public Offering [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares										900,000
Warrant issued										450,000
Gross proceeds from issuance of common stock										$ 18,000,000
Net proceeds from issuance of common stock										$ 16,100,000
July 2024 Follow On Overallotment Warrants [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant issued										67,500
Gross proceeds from issuance of common stock									2,700,000
Net proceeds from issuance of common stock									$ 2,500,000
Purchase of common stock										135,000
July 2024 Follow on Overallotment Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares										135.0000
October 2024 Follow On Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares								2,117,646
Price per share								$ 17.00
Warrants to purchase shares								2,117,646
Gross proceeds from issuance of common stock								$ 36,000,000
October 2024 Follow On Offering [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares								2,117,646
Number of shares of warrants								1,058,823
October 2024 Follow On Over Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Price per share								$ 21.25
Warrant expiry								Oct. 29, 2029
October 2024 Follow On Over Allotment Option [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of warrants								15,882
Warrants exercised								15,882
Private Placement [Member] \| Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Proceds from private placement		$ 378,500,000				$ 55,122,000
Proceds from private placement , gross			$ 400,000,000
Private Placement [Member] \| May 2025 Placement Agency Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Legal expenses					$ 150,000
May 2025 Private Placement [Member] \| Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds					$ 99,000,000
Market price per share					$ 27.00
Proceds from private placement					$ 105,000,003
Cash fee percentage					5.00%
Sale of common stock					3,888,889

SCHEDULE OF ALIP ACQUISITION (Details) $ in Thousands					3 Months Ended
SCHEDULE OF ALIP ACQUISITION (Details) $ in Thousands	Aug. 14, 2025 CAD ($)	Jan. 10, 2025 USD ($)	Dec. 18, 2024 USD ($)	Jun. 21, 2024 USD ($)	Dec. 31, 2025 USD ($)
Asset Acquisition [Line Items]
Total purchase price	$ 650	$ 8,500,000	$ 8,500,000		$ 8,500,000
ALIP Technology [Member]
Asset Acquisition [Line Items]
Total purchase price				$ 1,673,000
Cash (paid on closing)				50,000
Shares of Common Stock (issued on closing)				786,500
Contingent cash				50,000
Contingent Common Stock (fair value at closing)				$ 786,500

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial reporting and the rules and regulations of the Securities and Exchange Commission (“SEC”). References to ASC and ASU included herein refer to the Accounting Standards Codification and Accounting Standards Update established by the Financial Accounting Standards Board (“FASB”) as the source of authoritative U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

In management’s opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual audited consolidated financial statements. They include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of December 31, 2025, and its results of operations for the three months ended December 31, 2025 and 2024 and cash flows for the three months ended December 31, 2025 and 2024. The results for the three months ended December 31, 2025 are not necessarily indicative of the results expected for the year or any other periods. The condensed consolidated balance sheet as of September 30, 2025 has been derived from the Company’s audited consolidated financial statements.

Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents are stated at cost, which approximates market value, because of the short maturity of these instruments.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions made when accounting for items and matters such as, but not limited to, equity-based compensation, right-of-use assets and lease liabilities, and contingencies are reasonable, based on information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the unaudited condensed consolidated financial statements, as well as amounts reported on the unaudited condensed consolidated statements of operations during the periods presented. Actual results could differ from those estimates.

Fair Value Measurement

The Company measures certain financial assets and liabilities at fair value. Fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company uses a three-level hierarchy, which prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below.

Level 1 – Quoted prices in active markets for identical instruments.

Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.

Level 3 – Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the most stringent level of input that is significant to the fair value measurement. The carrying amount of certain financial instruments, including prepaid expenses and accounts payable, approximates fair value due to their short maturities.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains its cash balances at a financial institution and such amounts exceeded federally insured limits at December 31, 2025 and September 30, 2025. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Accounts Receivable

Accounts receivable include commercial accounts receivable associated with other income corresponding to consulting services provided by the Company. Accounts receivable are presented net of allowance for credit losses. Management estimates an allowance for credit losses by evaluating client-specific conditions, including adverse situations that may affect a client’s ability to pay, as well as both microeconomic and macroeconomic factors.

Prepaid Expenses

Prepaid expenses primarily relate to payments made to consultants and vendors in advance of the service being provided.

Property, Plant and Equipment

Property, plant and equipment are measured at cost less accumulated depreciation and impairment charges. When components of an item of property, plant and equipment have different useful lives, they are accounted for as separate items of property, plant and equipment and depreciated separately. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized in earnings.

In-process Research and Development

In-process research and development (“IPR&D”) represents incomplete research and development projects that had not reached technological feasibility as of their acquisition date in 2025. Due to the nature of IPR&D, the expected life is indefinite, and it will be evaluated periodically for attainment of technological feasibility or impairment. Technological feasibility is established when an enterprise has completed all planning, designing, coding and testing activities that are necessary to establish that a product can be produced to meet its design specifications including functions, features and technical performance requirements. IPR&D is amortized over its estimated useful life once technological feasibility is reached. As the Company has not yet completed all designing, coding and testing activities, management has determined that technological feasibility has not yet been reached. Management has not identified any indicators that would suggest any impairment of the IPR&D. If IPR&D is determined not to have technological feasibility or is abandoned, it will be impaired or written off at such time.

Depreciation

Depreciation is calculated over the depreciable amount, which is the cost of the asset less its residual value. Depreciation methods, useful lives and residual values are reviewed at each reporting period and are adjusted if appropriate. Assets are depreciated according to the straight-line method based on estimated useful lives as follows:

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Land		Not depreciated
Buildings		20 years

Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the associated lease.

Leases

The Company recognizes right-of-use assets and lease liabilities for leases with terms greater than 12 months. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. As of December 31, 2025 and September 30, 2025, the Company had two long-term operating leases.

Long-term leases (leases with initial terms greater than 12 months) are capitalized at the present value of the minimum lease payments not yet paid. The Company uses its incremental borrowing rate to determine the present value of the lease when the rate implicit in the lease is not readily determinable. Short-term leases (leases with an initial term of 12 months or less or leases that are cancelable by the lessee and lessor without significant penalties) are not capitalized but are expensed on a straight-line basis over the lease term.

Warrant Instruments

The Company accounts for warrants issued in connection with the private placement in accordance with the guidance contained in FASB ASC Topic 815, “Derivatives and Hedging”. Accordingly, the Company evaluated and classified the warrant instruments under equity treatment at their assigned values.

Investments in Equity – Related Party

The Company accounts for investments in equity that are within the scope of ASC 321-10, “Investments - Equity Securities” (“ASC 321-10”), as either (1) investments with a readily determinable fair value, which are recorded at fair value or (2) investments without a readily determinable fair value, which are recorded at cost less any impairment. Equity investments that are initially concluded to not have a readily determinable fair value are reassessed at each reporting period. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it measures the equity security at fair value as of the date that the observable transaction occurred using valuation techniques that are permitted under ASC 820, “Fair Value Measurement”.

As of December 31, 2025 and September 30, 2025, the Company had investments in equity of $2.0 million, representing the Company’s equity investment in LIST (see Note 8). The equity investments were accounted for in accordance with ASC 321-10, and the Company accounted for the equity investments at cost less impairment because there were no readily determinable fair values for these investments as of December 31, 2025. No impairment was recorded during the three months ended December 31, 2025. The investments were recognized as other assets on the Company’s condensed consolidated balance sheets.

Equity-Based Compensation

Equity-based compensation for employees and non-employees is measured using a fair value-based method for all equity-based awards. The Company recognizes equity-based compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting term. Vesting terms vary based on the individual grant terms. The Company estimates the fair value of an equity-based award using a closed option valuation (Black-Scholes) pricing model. Equity-based compensation is recorded as either a general and administrative expense or a research and development expense in the unaudited condensed consolidated statements of operations. The Company has elected to account for forfeitures of stock-based awards as they occur.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Black-Scholes pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.

The Company’s assumptions utilized in the Black-Scholes price model are as follows: (1) fair market value of stock price on date of grant; (2) the volatility of its underlying stock; which is estimated using a weighted average of the Company’s historical volatility, since it began trading, and the historical volatility of a group of comparable publicly traded companies due to the Company’s lack of trading history over the expected term; (3) expected dividend yield is zero as the Company does not anticipate paying any recurring cash dividends in the foreseeable future; (4) risk-free rate based on the United States Treasury yield curve in effect at the time of the grant for the period of the expected term; (5) expected term estimated based on the vesting and contractual term of the stock option grant.

Research and Development

Research and development (“R&D”) expenses represent costs incurred for designing and engineering products, including the costs of developing design tools, as well as the costs to acquire technology and other assets from third parties. All research and development costs related to product development are expensed as incurred.

Advertising Costs

Advertising costs are expensed as incurred and are recognized as a component of general and administrative expenses on the unaudited condensed consolidated statements of operations. Advertising costs expensed were approximately $73,500 and $93,501, respectively, for the three months ended December 31, 2025 and 2024.

Legal Contingencies

The Company is presently involved in two stockholder-initiated legal proceedings. One of such proceedings was dismissed at the trial court level in April 2025 but remains subject to appeal. The other proceeding is currently subject to a motion to dismiss. Given the status of these legal proceedings, the Company cannot reasonably estimate at December 31, 2025 the amount of any potential financial loss or cost that could result from these proceedings. The Company records liabilities for losses from legal proceedings when it determines that it is probable that the outcome in a legal proceeding will be unfavorable, and the amount of loss can be reasonably estimated.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when it is “more likely than not” that deferred tax assets will not be realized. On a regular basis, the Company evaluates the recoverability of deferred tax assets and the need for a valuation allowance. Such evaluations involve the application of significant judgment. The Company considers multiple factors in its evaluation of the need for a valuation allowance.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

On July 4, 2025, the U.S. federal government enacted tax legislation referred to as the One Big Beautiful Bill Act (“OBBBA”). The OBBBA, among other things, makes permanent 100% bonus depreciation for certain capital expenditures and immediate deduction for domestic research or experimental expenditures (R&D deduction). This legislation was effective for the Company’s consolidated financial statements for the year ended September 30, 2025, except for the R&D deduction which will be effective for the Company’s fiscal year 2026. The enactment of the OBBBA did not have a material impact on the Company’s consolidated financial statements for the year ended September 30, 2025. The Company is currently assessing the impact of the OBBBA on future periods.

Until an appropriate level of profitability is attained, the Company expects to maintain a full valuation allowance on its deferred tax assets. Any tax benefits or tax expense recorded on its condensed consolidated statements of operations will be offset with a corresponding valuation allowance until such time that the Company changes its determination related to the realization of deferred tax assets. In the event that the Company changes its determination as to the amount of deferred tax assets that can be realized, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period in which such a determination is made. For uncertain tax positions that meet a “more-likely-than-not” threshold, the Company recognizes the benefit of uncertain tax positions in the condensed consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the condensed consolidated statements of operations. All of the Company’s historical tax returns remain subject to examination by taxing jurisdictions. At December 31, 2025 and September 30, 2025, the Company does not believe it has any uncertain tax positions that would require either recognition or disclosure in the accompanying condensed consolidated financial statements.

Net Loss per Share

Basic earnings attributable to common shareholders is computed by dividing reported net income (loss) attributable to common shareholders by the weighted-average number of shares of Common Stock outstanding during the reporting period. Diluted earnings per share attributable to common shareholders is computed by dividing reported net income (loss) attributable to common shareholders by the sum of the weighted-average number of shares of Common Stock and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental shares of Common Stock issuable upon the exercise of share options, warrants, and RSUs and the incremental shares issuable upon conversion of similar instruments.

In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive are as follows as of December 31:

	2025		2024
Stock options		3,579,000		3,049,000
Warrants		2,987,150		3,896,477
Restricted share units		757,014		-
Total shares excluded		7,323,164		6,945,477

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Operating Segments

For the three months ended December 31, 2025 and 2024, the Company was managed as a single operating segment in accordance with the provisions in the FASB guidance on segment reporting, which establishes standards for, and requires disclosure of, certain financial information related to reportable operating segments and geographic regions. Furthermore, the Company determined that the Company’s Chief Executive Officer is the Chief Operating Decision Maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization as a whole.

Recent Accounting Pronouncements

The Company considers the applicability and impact of all ASUs issued by the FASB. In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures” (“ASU 2024-03”). ASU 2024-03 requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on its disclosures. There are no other accounting pronouncements which have been issued but are not yet effective that would have a material impact on the Company’s condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The amendment in the ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The ASU’s amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that adoption of ASU 2023-09 will have on its condensed consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

SCHEDULE OF STRAIGHT LINE METHOD BASED ON ESTIMATED USEFUL LIVES

Land		Not depreciated
Buildings		20 years

SCHEDULE OF SHARES EXCLUDED FROM DILUTED PER SHARE AMOUNT

	2025		2024
Stock options		3,579,000		3,049,000
Warrants		2,987,150		3,896,477
Restricted share units		757,014		-
Total shares excluded		7,323,164		6,945,477

Condensed Consolidated Statements of Operations And Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Operating expenses
General and administrative	$ 6,886,603	$ 2,494,570
Research and development	5,400,410	904,923
Change in fair value of contingent consideration	(727,500)	524,250
Loss from operations	11,559,513	3,923,743
Other income	5,013,557	810,381
Unrealized loss on marketable securities	(122,838)
Gain on settlement of accounts receivable	152,515
Net loss	(6,516,279)	(3,113,362)
Other comprehensive loss:
Cumulative translation adjustment	(10,720)
Comprehensive loss	$ (6,526,999)	$ (3,113,362)
Net loss per share of common stock:
Basic	$ (0.13)	$ (0.09)
Diluted	$ (0.13)	$ (0.09)
Weighted-average shares of common stock outstanding:
Basic	49,807,203	33,964,495
Diluted	49,807,203	33,964,495

SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITIES (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2025	Sep. 30, 2025
Right-of-use Assets And Lease Liabilities
Beginning of period	$ 2,560,896	$ 1,830,124
Additions		1,026,348
Amortization	(83,461)	(295,576)
End of period	$ 2,477,435	$ 2,560,896

LONG-TERM INVESTMENTS, RELATED PARTY

3 Months Ended

Dec. 31, 2025

Investments, All Other Investments [Abstract]

LONG-TERM INVESTMENTS, RELATED PARTY

8. LONG-TERM INVESTMENTS, RELATED PARTY

In August 2024, the Company invested $2,000,000 as an equity investment into LIS Technologies Inc. (“LIST”) (which is a related party), as part of its $11.88 million seed funding round. This additional capital into LIST was anticipated to help fuel the development of its proprietary, patented advanced laser enrichment technology.

Concurrently with our investment in LIST, we entered into an agreement with LIST to collaborate and assist in developing LIST’s technologies to secure a fuel supply for our future operations and the wider nuclear energy industry. The parties intend that LIST will provide the Company with enriched UF6 at no cost to be fabricated and sold to customers, with LIST to receive compensation as part of a profit-sharing arrangement to be agreed to between the companies in the future. Through collaboration with LIST, the Company anticipates building supportive facilities around LIST’s enrichment facility, including such facilities as deconversion and fuel fabrication.

The Company also leased approximately 7,000 square feet of dedicated space within its Oak Ridge, Tennessee, based nuclear technology facility to LIST to enable the next phase of the revitalization of its proprietary laser-based process. The Company leases this space to LIST for $7,000 per month. The lease became effective on September 2, 2024 and has a term ending on September 1, 2034.

The Company’s relationship with LIST is considered a related party transaction since the Company’s president and director, Jay Jiang Yu, also serves as an officer and director for LIST, and James Walker and Jaisun Garcha serve as consultants to LIST. The Company’s investment in LIST was unanimously approved by all of the Company’s disinterested independent directors.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Cash Equivalents

Cash Equivalents

Use of Estimates

Use of Estimates

Fair Value Measurement

Fair Value Measurement

Level 1 – Quoted prices in active markets for identical instruments.

Level 3 – Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Concentration of Credit Risk

Concentration of Credit Risk

Accounts Receivable

Accounts Receivable

Prepaid Expenses

Prepaid Expenses

Prepaid expenses primarily relate to payments made to consultants and vendors in advance of the service being provided.

Property, Plant and Equipment

Property, Plant and Equipment

In-process Research and Development

In-process Research and Development

Depreciation

Depreciation

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Land		Not depreciated
Buildings		20 years

Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the associated lease.

Leases

Leases

Warrant Instruments

Warrant Instruments

Investments in Equity – Related Party

Investments in Equity – Related Party

Equity-Based Compensation

Equity-Based Compensation

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Research and Development

Research and Development

Advertising Costs

Advertising Costs

Legal Contingencies

Legal Contingencies

Income Taxes

Income Taxes

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Net Loss per Share

Net Loss per Share

Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive are as follows as of December 31:

	2025		2024
Stock options		3,579,000		3,049,000
Warrants		2,987,150		3,896,477
Restricted share units		757,014		-
Total shares excluded		7,323,164		6,945,477

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Operating Segments

Operating Segments

Recent Accounting Pronouncements

Recent Accounting Pronouncements

SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
	Nov. 13, 2025	Dec. 31, 2025	Sep. 30, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted	423,766	20,000
2025 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, outstanding, beginning		350,748
Weighted- average grant date fair value per share, outstanding beginning		$ 29.18
Aggregate intrinsic value, outstanding, beginning		$ 10,235
Number of shares, granted		423,766	350,748
Weighted- average grant date fair value per share, granted		$ 29.18	$ 29.18
Aggregate intrinsic value, granted			$ 10,235
Number of shares, vested		(17,500)
Weighted- average grant date fair value per share, vested		$ 29.18
Aggregate intrinsic value, granted
Number of shares, outstanding, ending		757,014	350,748
Weighted- average grant date fair value per share, outstanding ending		$ 29.18	$ 29.18
Aggregate intrinsic value, outstanding, beginning		$ 10,235	$ 10,235

SCHEDULE OF STRAIGHT LINE METHOD BASED ON ESTIMATED USEFUL LIVES (Details)	Dec. 31, 2025
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Useful Life, Lease Term [Member]
Building [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	20 years

SCHEDULE OF ALLOCATION OF CONSIDERATION (Details) - Canadian Consents [Member]	Dec. 31, 2025 USD ($)
Restructuring Cost and Reserve [Line Items]
Cash consideration paid	$ 8,500,000
Less: Value of Consent Assets (subject to Canadian Consents) held in escrow	(250,000)
Add: Assumed liabilities related to Designated Contracts (excluding Canadian Contracts)	825,045
Total fair value of Acquired IPR&D Assets	$ 9,075,045

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

SCHEDULE OF LEASE EXPENSE (Details) - USD ($)	3 Months Ended
SCHEDULE OF LEASE EXPENSE (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Right-of-use Assets And Lease Liabilities
Operating lease cost	$ 158,694	$ 104,398

SCHEDULE OF SHARES EXCLUDED FROM DILUTED PER SHARE AMOUNT (Details) - shares	3 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded	7,323,164	6,945,477
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded	3,579,000	3,049,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded	2,987,150	3,896,477
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded	757,014

SCHEDULE OF CUMULATIVE OPTION ACTIVITY (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2025	Sep. 30, 2025	Sep. 30, 2024
Equity [Abstract]
Number of shares, outstanding, beginning	3,774,000	3,539,000
Weighted average exercise price per share, outstanding, beginning	$ 10.31	$ 2.34
Weighted average contractual term, outstanding	3 years 1 month 17 days	3 years 3 months	1 year 7 months 2 days
Aggregate intrinsic value, outstanding, beginning	$ 106,626	$ 42,720
Number of shares, granted		1,184,300
Weighted average exercise price per share, granted		$ 28.01
Aggregate intrinsic value, granted
Number of shares, forfeited		(5,300)
Weighted average exercise price per share, forfeited		$ 28.32
Aggregate intrinsic value, forfeited
Number of shares, exercised	(195,000)	(944,000)
Weighted average exercise price per share, exercised	$ 2.77	$ 2.55
Aggregate intrinsic value, exercised
Number of shares, outstanding, ending	3,579,000	3,774,000	3,539,000
Weighted average exercise price per share, outstanding, ending	$ 10.72	$ 10.31	$ 2.34
Aggregate intrinsic value, outstanding, ending	$ 52,292	$ 106,626	$ 42,720
Number of shares, outstanding , Exercisable at the end of period	3,235,000
Weighted average exercise price per share, Exercisable at the end of period	$ 8.99
Weighted average contractual term, Exercisable at the end of period	2 years 6 months
Aggregate intrinsic value, Exercisable at the end of period	$ 52,292

SCHEDULE OF PROPERTY , PLANT AND EQUIPMENT (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Sep. 30, 2025
Accumulated depreciation
Depreciation of building	$ (208,408)	$ (19,976)
Total property, plant and equipment, net	11,029,284		$ 9,783,777
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Beginning of period	10,149,332	1,700,000	1,700,000
Additions – land			330,000
Additions – building			4,000,234
Additions – leasehold improvements			3,103,000
Additions – construction in progress	1,453,915		1,016,098
End of period	11,603,247		10,149,332
Accumulated depreciation
Beginning of period	(365,555)	$ (10,393)	(10,393)
Depreciation of building	(69,978)		(133,975)
Depreciation of leasehold improvements	(138,430)		(221,187)
End of period	(573,963)		(365,555)
Total property, plant and equipment, net	$ 11,029,284		$ 9,783,777

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Sep. 30, 2025
Accounting Policies [Abstract]
Investments in equity	$ 2,000,000.0		$ 2,000,000.0
Impairment on investments in equity	0
Advertising costs	$ 73,500	$ 93,501

- Definition

+ References + Details

ACQUISITION OF ALIP TECHNOLOGY (Tables)

3 Months Ended

Dec. 31, 2025

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

SCHEDULE OF ALIP ACQUISITION

The ALIP Acquisition was recorded at its fair value as of June 21, 2024. The total purchase price was approximately $1.67 million and was comprised of the following:

SCHEDULE OF ALIP ACQUISITION

	Total
Cash (paid on closing)	$	50,000
Shares of Common Stock (issued on closing)		786,500
Contingent cash		50,000
Contingent Common Stock (fair value at closing)		786,500
Total purchase price	$	1,673,000

- Definition

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details

ORGANIZATION AND OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Sep. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value	$ 0.0001		$ 0.0001
Working capital	$ 576,432,889		$ 200,841,189
Accumulated deficit	64,017,136		57,500,857
Net loss	6,516,279	$ 3,113,362	40,067,076
Net cash used in operating activities	3,989,840	3,242,526	$ 19,621,963
Exercises of warrants	2,445,048	8,014,286
Exercises of stock options	540,000	$ 1,207,500
Net proceeds private placement offering	378,000,000
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Exercises of warrants	$ 2,500,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Sep. 30, 2025
OPERATING ACTIVITIES
Net loss	$ (6,516,279)	$ (3,113,362)	$ (40,067,076)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use assets	83,462	43,918
Depreciation	208,408	19,976
Equity-based compensation	2,072,690
Bank revaluation	731
Change in fair value of contingent consideration	(727,500)	524,250
Unrealized gain on marketable securities	122,838
Gain on settlement on accounts receivable	(152,515)
Change in assets and liabilities:
Accounts receivable	(86,381)
Prepaid expenses	(112,028)	(789,747)
Accounts payable and accrued liabilities	1,226,110	137,774
Due to related parties		(25,000)
Lease liabilities	(109,376)	(40,335)
Net cash used in operating activities	(3,989,840)	(3,242,526)	(19,621,963)
INVESTING ACTIVITIES
Deposits	(1,604,766)	(3,560,000)
Construction-in-progress	(1,453,915)
Net cash used in investing activities	(3,058,681)	(3,560,000)
FINANCING ACTIVITIES
Proceeds from common stock issuances	400,000,033	101,400,012
Offering costs	(21,520,711)	(9,058,856)
Proceeds from exercise of warrants	2,445,048	8,014,286
Proceeds from exercise of stock options	540,000	1,207,500
Payment of deferred offering costs	(135,500)
Net cash provided by financing activities	381,328,870	101,562,942
Net increase in cash and cash equivalents	374,280,349	94,760,416
Cash and cash equivalents, beginning of period	203,265,052	28,507,257	28,507,257
Effect of exchange rate changes on cash	(11,452)
Cash and cash equivalents, end of period	$ 577,533,949	$ 123,267,673	$ 203,265,052

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2025	Sep. 30, 2025
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	50,581,794	41,738,358
Common stock, shares outstanding	50,581,794	41,738,358

EQUITY (Tables)

3 Months Ended

Dec. 31, 2025

Equity [Abstract]

SCHEDULE OF CUMULATIVE OPTION ACTIVITY

A summary of cumulative option activity under the 2023 Stock Option Plans and the 2025 Equity Plan is as follows:

SCHEDULE OF CUMULATIVE OPTION ACTIVITY

	Options outstanding
	Number of shares			Weighted- average exercise price per share		Weighted- average contractual term (in years)		Aggregate intrinsic value (in thousands)

Outstanding – September 30, 2024		3,539,000		$	2.34		1.59	$	42,720
Options granted		1,184,300			28.01				—
Options forfeited		(5,300	)		28.32		—		—
Options exercised		(944,000	)		2.55		—		—
Outstanding – September 30, 2025		3,774,000		$	10.31		3.25	$	106,626
Options exercised		(195,000	)		2.77		—		—
Outstanding – December 31, 2025		3,579,000		$	10.72		3.13	$	52,292
Exercisable at the end of period		3,235,000		$	8.99		2.50	$	52,292

SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY

A summary of cumulative restricted stock unit activity under the 2025 Equity Plan is as follows:

	RSUs outstanding
	Number of shares			Weighted- average grant date fair value per share		Aggregate fair value (in thousands)

Outstanding –September 30, 2024		—		$	—	$	—
RSUs granted		350,748			29.18		10,235
Outstanding and unvested – September 30, 2025		350,748		$	29.18	$	10,235
RSUs granted		423,766			29.18		10,235
RSUs vested (stock issued)		(17,500	)		29.18		—
Outstanding and unvested – December 31, 2025		757,014		$	29.18	$	10,235

SCHEDULE OF CUMULATIVE WARRANT ACTIVITY

A summary of cumulative warrant activity is as follows:

	Warrant Shares outstanding
				Weighted- average		Weighted- average
	Number of			exercise price		contractual term
	shares			per share		(in years)

Outstanding – September 30, 2024		817,864		$	17.28		4.79
Warrants issued		3,717,648			23.05		5.00
Warrants exercised		(1,408,193	)		16.71		-
Outstanding – September 30, 2025		3,127,319		$	24.40		4.12
Warrants exercised		(140,169	)		17.44		-
Outstanding – December 31, 2025		2,987,150		$	24.72		3.88

USNC ASSET ACQUISITION

3 Months Ended

Dec. 31, 2025

Usnc Asset Acquisition

USNC ASSET ACQUISITION

9. USNC ASSET ACQUISITION

On December 18, 2024, the Company entered into an asset purchase agreement (as amended, the “USNC Agreement”) with Ultra Safe Nuclear Corporation and certain of its subsidiaries (collectively, “USNC”) to acquire select nuclear energy technology assets (the “USNC Assets”) on an as-is, where-is basis, including USNC’s micro modular nuclear reactor business previously marketed as a MMR® Microreactor Energy System, which the Company has renamed “KRONOS MMR^TM” (“KRONOS Business”), and transportable fission power system technology business previously marketed as a Pylon Transportable Reactor Platform, which the Company has renamed “LOKI MMR^TM” (“LOKI Business”). The acquired assets included certain contracts, intellectual property rights, and a demonstration project, free and clear of any liens other than certain specified liabilities of USNC that were assumed, for a total purchase price of $8.5 million in cash through an auction process (“Auction”) conducted pursuant to Section 363 of the U.S. Bankruptcy Code in connection with USNC’s pending Chapter 11 bankruptcy proceedings. On December 18, 2024, the United States Bankruptcy Court for the District of Delaware, the Bankruptcy Court overseeing USNC’s bankruptcy held a hearing where it approved the sale of the USNC Assets to the Company.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

9. USNC ASSET ACQUISITION (continued)

On January 10, 2025, we closed the acquisition (the “USNC Closing”) of the USNC Assets related to the KRONOS Business and the LOKI Business from USNC. The USNC Assets were acquired free and clear of any liens other than certain specified liabilities of USNC that were assumed, for a total purchase price of $8.5 million in cash through an auction conducted pursuant to Section 363 of the U.S. Bankruptcy Code in connection with USNC’s pending Chapter 11 bankruptcy proceedings. The USNC Assets included (i) five contracts with third-party collaborators, (ii) 38 issued, pending or published patents, 16 registered, pending or published trademarks, and any other technology and intellectual property related to the acquired assets, (iii) rights related to a demonstration project related to the KRONOS MMR™ Energy System in the United States and (iv) the business records of the USNC Assets and related rights. We acquired these assets through two new wholly owned subsidiaries incorporated in Nevada.

The USNC Assets also included certain Canadian assets relating to both the KRONOS MMR™ Energy System and certain Canadian intellectual property rights relating to the LOKI MMR™ (the “Canadian Assets”). The Canadian Assets include, among other assets, (i) three contracts with Canadian authorities, including a license application (the “Chalk River License Application”) with the Canadian Nuclear Safety Commission (“CNSC”) associated with a KRONOS MMR^TM reactor demonstration project at Chalk River Laboratories located in Ontario, Canada (the “Chalk River Project”), (ii) the equity interests of a Canadian partnership that was believed at the time to hold the Chalk River License Application (the “Canadian Partnership”), and (iii) rights related to the Chalk River Project. The transfer of the Chalk River License Application and certain other of the Canadian Assets (such assets, the “Consent Assets”) required the consent of certain Canadian governmental entities, including the CNSC (the “Canadian Consents”). We established an escrow of $250,000 deposited at the closing securing the Canadian Consents. If the Canadian Consents were not received within 90 days after the closing, we had the right to terminate the acquisition of the Consent Assets, receive the return of $250,000 held in escrow and forfeit our rights to the Consent Assets. Our right to acquire the Consent Assets was established pursuant to an option arrangement with our Chairman and President and his affiliated entities as described below.

We had a limited amount of time to conduct due diligence on the USNC Assets, particularly the Canadian Assets. Moreover, we were made aware at that time that certain Consent Assets (specifically the Canadian Partnership) could be encumbered by liabilities that could not be cleared through USNC’s U.S. bankruptcy process, thus creating a risk to us should we assume such liabilities. To enable our ability to continue diligence of the Consent Assets to ensure we acquired the correct assets and did not assume or become exposed to any unknown liabilities, on the closing date of the USNC Asset acquisition, we assigned our rights to acquire the Consent Assets to Jay Jiang Yu, our founder, President, Secretary and Treasurer, and Chairman of the Board, and certain existing Canadian entities owned or controlled by Mr. Yu (the “Yu Entities”). Accordingly, on January 10, 2025, we entered into an option agreement (“Yu Option Agreement”) with Mr. Yu and Yu Entities, pursuant to which we received an option back from Mr. Yu and the Yu Entities to acquire for nominal consideration, for a period of five years beginning with the receipt by the Yu Entities of the Consent Assets upon receiving the Canadian Consents, any or all of the equity interests of the Yu Entities or the Canadian Partnership, the other Consent Assets or the material assets and business of the Canadian Partnership. The assignment of the right to acquire the Consent Assets and the Yu Option Agreement were unanimously approved by our disinterested directors. Given the uncertainties regarding the Consent Assets at that time, we believe this option arrangement was the most efficient and cost-effective structure (particularly since the option was exercisable by us for only nominal consideration) for us to close the bankruptcy sale and secure the right to acquire Consent Assets, while also preserving our ability to progress the KRONOS project in Canada and facilitate the Canadian Consents.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

9. USNC ASSET ACQUISITION (Continued)

During 2025, we sought Canadian Consents for the Consent Assets (most notably, the Chalk River License Application). As part of our continuing due diligence, we learned that a USNC affiliate called Global First Power Ltd. (“GFPL”), and not the Canadian Partnership, was in fact the holder of the Chalk River License Application. Further, we were informed by the CNSC that the Chalk River License Application could not be transferred and that only GFPL itself could complete the Chalk River License Application and obtain the license for the Chalk River Project or, alternatively, we or our subsidiaries or designees would need to file a new application with the CNSC. Accordingly, we determined that the most efficient course of action for our company to continue the Chalk River Project would be for us to acquire GFPL itself and thereby acquire the Chalk River License Application. As a result, on August 14, 2025, The RPWI Liquidating Trust, a Delaware liquidating trust created pursuant to USNC’s plan of liquidation in bankruptcy, GFPL, our company and our subsidiary KRONOS MMR Inc. entered into a Purchase Agreement (the “GFPL Purchase Agreement”) pursuant to which KRONOS MMR agreed to purchase all of the equity interests of GFPL and any other assets of GFPL that are specified in the GFPL Purchase Agreement (including the rights to the Chalk River License Application), free and clear of all liens, claims, encumbrances and other interests. The purchase price for GFPL was our assumption of an approximately CAD $0.65 million liability, which was the amount owed by GFPL to the CNSC for pre-petition bankruptcy claims, plus any other amounts payable to CNSC for the Chalk River License Application which first arise and relate to, or become due and payable in the ordinary course after the closing of such acquisition, plus a $15,000 expense reimbursement allowance. On September 2, 2025, the GFPL Purchase Agreement and the transactions contemplated thereby were approved by the Bankruptcy Court, and on October 16, 2025, such transaction was closed. We expect to pay the CAD $0.65 million assumed liability using cash on hand in the near future. In late October 2025, we announced our rebranding of GFPL to the name True North Nuclear.

As a result of the foregoing, neither the Yu Entities nor our company formally acquired the Consent Assets, and given our subsequent due diligence and discussions with CNSC following our acquisition of the USNC Assets, we have determined that (i) our acquisition of GFPL provides us with all of the rights and assets we require from USNC to progress a potential Chalk River Project, (ii) the Consent Assets subject to the Yu Option Agreement are immaterial to our plans and need not be acquired, with the result that we expect to terminate the Yu Option Agreement and (iii) given that the Canadian Consents were not achieved on a timely basis, we are seeking a return of the $250,000 escrow amount.

The total consideration paid at closing for the USNC Assets was $8.5 million in cash. The Company accounted for the transaction as an asset acquisition under ASC 805-50, “Business Combinations – Asset Acquisition”, as the acquired set of assets did not meet the definition of a business. The fair value of the identifiable assets was determined using the Historical Transaction Method under the Market Approach.

The fair value allocation of the consideration transferred is as follows:

SCHEDULE OF ALLOCATION OF CONSIDERATION

	Total
Cash consideration paid	$	8,500,000
Less: Value of Consent Assets (subject to Canadian Consents) held in escrow		(250,000	)
Add: Assumed liabilities related to Designated Contracts (excluding Canadian Contracts)		825,045
Total fair value of Acquired IPR&D Assets	$	9,075,045

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

9. USNC ASSET ACQUISITION (Continued)

The fair value was attributed to IPR&D assets associated with both the KRONOS Business and the LOKI Business. The acquired IPR&D assets are considered an indefinite-lived intangible asset and will not be amortized until the underlying technologies are placed into service. The Company will test the assets for impairment annually, or more frequently if events or changes in circumstances indicate potential impairment.

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Sep. 30, 2025
Current assets:
Cash and cash equivalents	$ 577,533,949	$ 203,265,052
Accounts receivable, net	86,381	250,000
Prepaid expenses	1,014,889	902,861
Deposits, current	1,850,000	250,000
Marketable securities, at fair value	279,677
Total current assets	580,764,896	204,667,913
Deferred offering costs	435,500	300,000
Deposits, non-current	274,001	269,235
Property, plant and equipment, net	11,029,284	9,783,777
Right-of-use assets	2,477,435	2,560,896
Long-term investments, related party	2,000,000	2,000,000
In-process research and development	9,075,045	9,075,045
Total assets	606,056,161	228,656,866
Current liabilities:
Accounts payable and accrued liabilities	2,540,706	1,314,596
Lease liabilities, current	540,801	534,128
Contingent consideration	1,250,500	1,978,000
Total current liabilities	4,332,007	3,826,724
Lease liabilities, non-current	2,145,365	2,261,414
Total liabilities	6,477,372	6,088,138
Stockholders’ equity
Preferred stock, $0.0001 par value; 25,000,000 authorized as of December 31, 2025 and September 30, 2025; none issued and outstanding as of December 31, 2025 and September 30, 2025
Common stock, $0.0001 par value; 275,000,000 authorized as of December 31, 2025 and September 30, 2025; 50,581,794 and 41,738,358 shares issued and outstanding as of December 31, 2025 and September 30, 2025, respectively	5,056	4,173
Additional paid-in capital	663,601,589	280,065,412
Accumulated deficit	(64,017,136)	(57,500,857)
Accumulated other comprehensive loss	(10,720)
Total stockholders’ equity	599,578,789	222,568,728
Total liabilities and stockholders’ equity	$ 606,056,161	$ 228,656,866

RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

3 Months Ended

Dec. 31, 2025

Right-of-use Assets And Lease Liabilities

RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

	December 31, 2025			September 30, 2025
Right-of-use assets
Beginning of period	$	2,560,896		$	1,830,124
Additions		-			1,026,348
Amortization		(83,461	)		(295,576	)
End of period	$	2,477,435		$	2,560,896

As of December 31, 2025, the Company had two long-term operating leases corresponding to (1) its corporate headquarters located at 10 Times Square, 30th Floor, New York, New York, and (2) space being used as a technology demonstration facility in Westchester County, New York. Lease components in the Company’s long-term operating leases are accounted for following the guidance in ASC Topic 842, “Leases” (“ASC 842”), for the capitalization of long-term leases. At December 31, 2025, the lease liability was equal to the present value of the remaining lease payments, discounted using a borrowing rate based on similar debt.

Balance sheet information related to the Company’s leases is presented below.

SCHEDULE OF BALANCE SHEET INFORMATION

Operating leases:	December 31, 2025		September 30, 2025
Operating right-of-use assets	$	2,477,435	$	2,560,896
Operating lease liabilities, current		540,801		534,128
Operating lease liabilities, long term		2,145,365		2,261,414

The following provides details of the Company’s lease expense:

SCHEDULE OF LEASE EXPENSE

Lease cost:	2025		2024
	Three Months Ended December 31,
Lease cost:	2025		2024
Operating lease cost	$	158,694	$	104,398

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)

Other information related to leases is presented below.

measurement of lease liabilities:	2025		2024
Cash paid for amounts included in the	Three Months Ended December 31,
measurement of lease liabilities:	2025		2024
Operating cash outflows from operating leases	$	154,335	$	100,815

	December 31, 2025
Weighted-average discount rate – operating lease		11.7	%
Weighted-average remaining lease term – operating lease (in years)		5.56

As of December 31 2025, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows:

For the Years Ended September 30,
2026	$	471,998
2027		641,992
2028		658,041
2029		674,493
Thereafter		1,142,669
Total future minimum lease payments, undiscounted		3,589,193
Less: Imputed interest for leases in excess of one year		(903,027	)
Present value of future minimum lease payments		2,686,166
Less: Current portion of lease liabilities		(540,801	)
Total lease liabilities, less current portion	$	2,145,365

OTHER INCOME

3 Months Ended

Dec. 31, 2025

Other Income and Expenses [Abstract]

OTHER INCOME

3. OTHER INCOME

During the three months ended December 31, 2025, the Company earned interest income of $4,920,707 on its cash and cash equivalents held at a financial institution, earned $71,850 from consulting services, and earned $21,000 from a lease agreement (see Note 8). During the three months ended December 31, 2024, the Company earned interest income of $789,381 on its cash and cash equivalents held at a financial institution and earned $21,000 from a lease agreement (see Note 8).

RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)

3 Months Ended

Dec. 31, 2025

Right-of-use Assets And Lease Liabilities

SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITIES

	December 31, 2025			September 30, 2025
Right-of-use assets
Beginning of period	$	2,560,896		$	1,830,124
Additions		-			1,026,348
Amortization		(83,461	)		(295,576	)
End of period	$	2,477,435		$	2,560,896

SCHEDULE OF BALANCE SHEET INFORMATION

Balance sheet information related to the Company’s leases is presented below.

SCHEDULE OF BALANCE SHEET INFORMATION

Operating leases:	December 31, 2025		September 30, 2025
Operating right-of-use assets	$	2,477,435	$	2,560,896
Operating lease liabilities, current		540,801		534,128
Operating lease liabilities, long term		2,145,365		2,261,414

SCHEDULE OF LEASE EXPENSE

The following provides details of the Company’s lease expense:

SCHEDULE OF LEASE EXPENSE

Lease cost:	2025		2024
	Three Months Ended December 31,
Lease cost:	2025		2024
Operating lease cost	$	158,694	$	104,398

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

Other information related to leases is presented below.

measurement of lease liabilities:	2025		2024
Cash paid for amounts included in the	Three Months Ended December 31,
measurement of lease liabilities:	2025		2024
Operating cash outflows from operating leases	$	154,335	$	100,815

	December 31, 2025
Weighted-average discount rate – operating lease		11.7	%
Weighted-average remaining lease term – operating lease (in years)		5.56

SCHEDULE OF EXPECTED ANNUAL MINIMUM LEASE PAYMENTS

As of December 31 2025, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows:

For the Years Ended September 30,
2026	$	471,998
2027		641,992
2028		658,041
2029		674,493
Thereafter		1,142,669
Total future minimum lease payments, undiscounted		3,589,193
Less: Imputed interest for leases in excess of one year		(903,027	)
Present value of future minimum lease payments		2,686,166
Less: Current portion of lease liabilities		(540,801	)
Total lease liabilities, less current portion	$	2,145,365

USNC ASSET ACQUISITION (Details Narrative) $ in Thousands				3 Months Ended
USNC ASSET ACQUISITION (Details Narrative) $ in Thousands	Aug. 14, 2025 CAD ($)	Jan. 10, 2025 USD ($)	Dec. 18, 2024 USD ($)	Dec. 31, 2025 USD ($)	Aug. 14, 2025 USD ($)
Usnc Asset Acquisition
Total purchase price	$ 650	$ 8,500,000	$ 8,500,000	$ 8,500,000
Escrow deposit			$ 250,000
Held in escrow				250,000
Reimbursement allowance					$ 15,000
Expect to pay assumed liability	$ 650
Escrow amount				$ 250,000

ORGANIZATION AND OPERATIONS AND BASIS OF PRESENTATION

3 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND OPERATIONS AND BASIS OF PRESENTATION

1. ORGANIZATION AND OPERATIONS AND BASIS OF PRESENTATION

NANO Nuclear Energy Inc. (“NANO”, the “Company”, “we”, “us”, “our” and similar terminology) was incorporated under the laws of the State of Nevada on February 8, 2022 (“Inception”) and is headquartered in New York, New York. The Company is an emerging nuclear energy company developing smaller, simpler, and safer advanced reactors utilizing proprietary microreactor designs, intellectual property and research methods.

With the goal of vertical integration across key aspects of the nuclear fuel supply chain, the Company is principally focused on the following four business lines as part of its development strategy:

	●	*Nuclear Reactor Business. The Company’s nuclear microreactors currently in development are (i) the fixed installation KRONOS MMR™ Energy System, (ii) ZEUS™, a portable modular solid core battery reactor, and (iii) the space focused, portable LOKI MMR™. The KRONOS MMR^™* reactor is the primary focus of the company given it has a high technology readiness level owing to the reactor being a high-temperature gas-cooled reactor that has benefitted from over a decade of time, work and resources invested into its design by its prior owner. Our KRONOS MMR^™ reactor is the closest to licensing and eventual deployment, so a substantial majority of the Company’s investment is focused on advancing this reactor through development, prototype construction, testing and regulatory licensing. The KRONOS MMR^™ reactor targets new markets beyond those targeted by the Company’s smaller microreactors, which are designed for remote locations, such as island and remote communities, military applications, remote industry such as mining projects or oil and gas projects. The KRONOS MMR^™ reactor is targeting AI and data centers for the technology industry, larger industrial applications, industrial heat for various industries, and certain military applications . The LOKI MMR^™ will target extra-terrestrial applications and applications requiring smaller energy needs and reactor portability. The ZEUS™ microreactor is also targeting applications with smaller energy needs, including military applications requiring reactor portability. Given that the LOKI MMR^™ and ZEUS™ microreactors also fit within the high-temperature gas-cooled reactor family, we believe each of these reactors can directly benefit in a capital efficient way from the advancement of The KRONOS MMR^™ reactor through the licensing process, and from any data or learnings generated from demonstrating or operating the reactor. The Company envisions readily replaceable microreactors which it can provide to customers in several sectors, including data centers, artificial intelligence computer and quantum computing; crypto mining; military applications; disaster relief; transportation (including shipping); mining projects; water desalination and green hydrogen plants; remote habitation, and space exploration. The KRONOS™ and LOKI™ designs and related intellectual property and other assets were acquired on January 10, 2025 (see Note 9 for further information). Through its subsidiary, Nano Nuclear Space Inc., the Company is seeking to explore the potential commercial applications of developing micronuclear reactor technology in space.

	●	Fuel Supply Chain Business. Through its subsidiary, HALEU Energy Fuel Inc., and in coordination with the Department of Energy (“DOE”), the Company is also seeking to develop a domestic low-enriched uranium (LEU) and high-assay low-enriched uranium (HALEU) fuel supply chain to supply fuel not only for its own reactors but also to the broader advanced nuclear reactor industry. In December 2024, the Company announced that LIS Technologies Inc., a related party through common ownership and management (“LIST”) (see Note 8), and the Company were selected by the DOE to participate as one of six contract awardees in the DOE’s Low-Enriched Uranium (LEU) Enrichment Acquisition Program (“LEU Acquisition Program”). Under the contract awarded to LIST, LIST was selected as the prime contractor, with the Company as the key subcontractor bringing the Company’s technical and regulatory expertise in advanced nuclear solutions to the collaboration (see Note 8 for further information). The Company is also evaluating ways to participate in other key aspects of the nuclear fuel supply chain in areas such as conversion through commercial agreements and acquisitions to achieve its vertical integration strategy in collaboration with LIST.

	●	Fuel Transportation Business. Through its subsidiary, Advanced Fuel Transportation Inc., the Company is developing a high-capacity HALEU transportation product, capable of moving commercial quantities of HALEU fuel around North America. The Company is also examining strategic acquisitions within the nuclear transportation industry to provide the Company with the in-house capability to move its own materials and reactors, although as of the date of these unaudited condensed consolidated financial statements, the Company has not entered into any definitive agreements with any third party for such acquisitions.

NANO NUCLEAR ENERGY INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2025

1. ORGANIZATION AND OPERATIONS AND BASIS OF PRESENTATION (Continued)

●

Nuclear Consultation Services. The Company is also evaluating ways to quickly enhance its internal engineering and technical capabilities while also providing nuclear service support and consultation services for the expanding and resurgent nuclear energy industry, both domestically and internationally. We are currently evaluating strategic acquisitions or collaborations to expand our business operations and formally establish our consulting services, and have commenced several material discussions with potential targets for such acquisitions or collaborations, but as of the date of these unaudited condensed consolidated financial statements, we have not entered into any definitive agreements for such acquisitions or collaborations. In combination with our intention to acquire existing revenue generating consultancy businesses, we are focusing on building our own internal nuclear consultation business in coordination with certain outside academic institutions. As of the date of this Report, we have not yet formally launched our nuclear consultation business, as formal launch of this business is dependent on success in acquiring existing businesses, although we generated a small amount of revenue during 2025 from providing such services.

These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned legal subsidiaries, American Uranium Inc., HALEU Energy Fuel Inc., Advanced Fuel Transportation Inc., Nano Nuclear Space Inc., KRONOS MMR Inc., LOKI MMR Inc., and True North Nuclear Ltd. Each of these subsidiaries is a Nevada corporation except for True North Nuclear Ltd., which is a Canadian corporation.

As used herein, the term “Common Stock” refers to the common stock, $0.0001 par value per share, of the Company.

Liquidity

These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. At December 31, 2025, the Company had working capital of $576,432,889 and accumulated deficit of $64,017,136. For the three months ended December 31, 2025, the Company had net loss of $6,516,279, and negative cash flows from operations of $3,989,840. At September 30, 2025, the Company had working capital of $200,841,189 and accumulated deficit of $57,500,857. For the year ended September 30, 2025, the Company had net loss of $40,067,076, and negative cash flows from operations of $19,621,963. The ability of the Company to continue as a going concern is dependent on the Company’s ability to secure financing from capital markets or other sources, including investors, loans, government grants or alternative funding and, ultimately, on the Company’s ability to generate revenue and profitable operations. Management is of the opinion that sufficient working capital is available to meet the Company’s liabilities and commitments as they become due at least for the next twelve months after the date the unaudited condensed consolidated financial statements are issued to conform to the going concern uncertainty period. During the three months ended December 31, 2025, the Company received approximately $2.5 million from exercises of warrants, $0.5 million from exercises of stock options, and net proceeds of approximately $378 million from the Company’s private placement offering. In order to achieve the Company’s long-term strategy, the Company expects to raise additional capital or secure other sources of financing to support its growth in the future.

SCHEDULE OF CUMULATIVE WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Dec. 31, 2025	Sep. 30, 2025	Sep. 30, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrant shares, outstanding, beginning	3,127,319	817,864
Weighted average exercise price per share, outstanding, beginning	$ 24.40	$ 17.28
Weighted average contractual term (in years), outstanding	3 years 10 months 17 days	4 years 1 month 13 days	4 years 9 months 14 days
Number of shares warrants issued		3,717,648
Weighted average exercise price per share, issued		$ 23.05
Weighted average contractual term (in years), outstanding, warrant issued		5 years
Number of shares warrants exercised	(140,169)	(1,408,193)
Weighted average exercise price per share, exercised	$ 17.44	$ 16.71
Number of warrant shares, outstanding, Ending	2,987,150	3,127,319	817,864
Weighted average exercise price per share, outstanding, ending	$ 24.72	$ 24.40	$ 17.28

PROPERTY, PLANT AND EQUIPMENT (Tables)

3 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY , PLANT AND EQUIPMENT

	December 31, 2025			September 30, 2025
	Land, buildings and leasehold improvements			Land, buildings and leasehold improvements
Cost
Beginning of period	$	10,149,332		$	1,700,000
Additions – land		-			330,000
Additions – building		-			4,000,234
Additions – leasehold improvements		-			3,103,000
Additions – construction in progress		1,453,915			1,016,098
End of period		11,603,247			10,149,332

Accumulated depreciation
Beginning of period		(365,555	)		(10,393	)
Depreciation of building		(69,978	)		(133,975	)
Depreciation of leasehold improvements		(138,430	)		(221,187	)
End of period		(573,963	)		(365,555	)

Total property, plant and equipment, net	$	11,029,284		$	9,783,777

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) - USD ($)	3 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Right-of-use Assets And Lease Liabilities
Operating cash outflows from operating leases	$ 154,335	$ 100,815
Weighted-average discount rate - operating lease	11.70%
Weighted-average remaining lease term - operating lease (in years)	5 years 6 months 21 days

SCHEDULE OF BALANCE SHEET INFORMATION (Details) - USD ($)	Dec. 31, 2025	Sep. 30, 2025	Sep. 30, 2024
Right-of-use Assets And Lease Liabilities
Operating right-of-use assets	$ 2,477,435	$ 2,560,896	$ 1,830,124
Operating lease liabilities, current	540,801	534,128
Operating lease liabilities, long term	$ 2,145,365	$ 2,261,414

PROPERTY, PLANT AND EQUIPMENT (Details Narrative)	3 Months Ended		12 Months Ended
PROPERTY, PLANT AND EQUIPMENT (Details Narrative)	Dec. 31, 2025 USD ($) ft²	Dec. 31, 2024 USD ($)	Sep. 30, 2025 USD ($)	Jul. 31, 2025 USD ($)	Jul. 31, 2025 ft²	Jul. 31, 2025 a	Aug. 31, 2024 USD ($)	Aug. 31, 2024 ft²	Aug. 31, 2024 a
Property, Plant and Equipment [Line Items]
Area of land	7,000				23,537	2.75		14,000	1.64
Money spend on acquisition of land				$ 3,500,000			$ 1,700,000
Depreciation	$ 208,408	$ 19,976
Nuclear Technology Headquaters [Member]
Property, Plant and Equipment [Line Items]
Depreciation	30,353		$ 94,351
KRONOSMMR Microreactor Energy System [Member]
Property, Plant and Equipment [Line Items]
Depreciation	$ 39,625		$ 39,625

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jan. 01, 2026	Dec. 31, 2025	Dec. 31, 2024	Sep. 30, 2025	Oct. 23, 2024
Subsequent Event [Line Items]
Number of shares stock options exercised		195,000		944,000
Proceeds from stock option exercised		$ 540,000	$ 1,207,500
Stock options were exercised		3,235,000
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares purchase of warrants					105,882
Number of shares stock options exercised		195,000	490,000
Number of shares purchase of warrants		8,490,767	4,935,294
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from warrant exercised	$ 1,050,000
Number of shares purchase of warrants	350,000
Exercise price per share	$ 3.00
Stock options were exercised	350,000
Subsequent Event [Member] \| Underwriter Warrants [Member]
Subsequent Event [Line Items]
Number of shares purchase of warrants	1,000
Price per share	$ 20.00
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of shares purchase of warrants	500
Purchase of shares	500
Proceeds from warrant exercised	$ 10,000
Subsequent Event [Member] \| Warrant One [Member]
Subsequent Event [Line Items]
Number of shares purchase of warrants	1,000
Price per share	$ 17.00
Proceeds from warrant exercised	$ 8,500
Subsequent Event [Member] \| Warrant Two [Member]
Subsequent Event [Line Items]
Number of shares stock options exercised	1,150,000
Number of shares purchase of warrants	1,150,000
Exercise price per share	$ 1.50
Proceeds from stock option exercised	$ 1,725,000